Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	testosterone 6-beta-hydroxylase activity	CYP3A7 CYP3A4 CYP3A5	3.79e-06	5	146	3	GO:0050649
GeneOntologyMolecularFunction	estrogen 2-hydroxylase activity	CYP3A7 CYP3A4 CYP3A5	2.09e-05	8	146	3	GO:0101021
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP3A7 CYP3A4 CYP3A5	6.05e-05	11	146	3	GO:0101020
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP3A7 CYP3A4 CYP3A5	1.31e-04	14	146	3	GO:0008401
GeneOntologyMolecularFunction	testosterone 16-alpha-hydroxylase activity	CYP3A4 CYP3A5	3.16e-04	4	146	2	GO:0008390
GeneOntologyMolecularFunction	microtubule binding	MAP9 KIF1A GAS2L3 CETN2 LRRK2 SPAG8 NAV3 KIF14 MACF1	4.49e-04	308	146	9	GO:0008017
GeneOntologyMolecularFunction	vitamin D 23-hydroxylase activity	CYP3A4 CYP3A5	5.23e-04	5	146	2	GO:0062179
GeneOntologyMolecularFunction	1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	CYP3A4 CYP3A5	5.23e-04	5	146	2	GO:0062181
GeneOntologyMolecularFunction	cytoskeletal anchor activity	ANK2 ANK3 GAS2L3	6.92e-04	24	146	3	GO:0008093
GeneOntologyMolecularFunction	vitamin D3 25-hydroxylase activity	CYP3A4 CYP3A5	7.81e-04	6	146	2	GO:0030343
GeneOntologyMolecularFunction	vitamin D 24-hydroxylase activity	CYP3A4 CYP3A5	7.81e-04	6	146	2	GO:0070576
GeneOntologyMolecularFunction	vitamin D 25-hydroxylase activity	CYP3A4 CYP3A5	1.09e-03	7	146	2	GO:0070643
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP3A4 CYP3A5	1.44e-03	8	146	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP3A4 CYP3A5	1.44e-03	8	146	2	GO:0034875
GeneOntologyMolecularFunction	cysteine-type deubiquitinase activity	USP17L21 USP17L12 USP28 USP43 USP42	1.51e-03	114	146	5	GO:0004843
GeneOntologyBiologicalProcess	Golgi to plasma membrane protein transport	GGA2 ANK3 ACSL3 ATP2C1 MACF1	1.67e-05	45	147	5	GO:0043001
GeneOntologyBiologicalProcess	lipid hydroxylation	CYP3A7 CYP3A4 CYP3A5	2.89e-05	9	147	3	GO:0002933
Domain	Cyt_P450_E_grp-II	CYP3A7 CYP3A4 CYP3A5	4.35e-06	5	143	3	IPR002402
Domain	Cyt_P450_E_CYP3A	CYP3A7 CYP3A4 CYP3A5	8.64e-06	6	143	3	IPR008072
Domain	-	WDR64 LRRK2 EDC4 DMXL1 UTP18 SEMA6D GTF3C2 CDC40 WDSUB1 RIC1 WDR72	5.23e-05	333	143	11	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	WDR64 LRRK2 EDC4 DMXL1 UTP18 SEMA6D GTF3C2 CDC40 WDSUB1 RIC1 WDR72	5.52e-05	335	143	11	IPR015943
Domain	Laminin_G	COL12A1 COL20A1 NRXN3 EGFLAM USH2A	8.11e-05	58	143	5	IPR001791
Domain	WD40_repeat_dom	WDR64 LRRK2 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 RIC1 WDR72	9.87e-05	297	143	10	IPR017986
Domain	SEA	MUC16 TMPRSS11F MUC3A	1.50e-04	14	143	3	SM00200
Domain	USP_CS	USP17L21 USP17L12 USP28 USP43 USP42	1.51e-04	66	143	5	IPR018200
Domain	USP_1	USP17L21 USP17L12 USP28 USP43 USP42	1.99e-04	70	143	5	PS00972
Domain	UCH	USP17L21 USP17L12 USP28 USP43 USP42	2.13e-04	71	143	5	PF00443
Domain	USP_2	USP17L21 USP17L12 USP28 USP43 USP42	2.13e-04	71	143	5	PS00973
Domain	WD40	WDR64 LRRK2 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 WDR72	2.26e-04	268	143	9	SM00320
Domain	USP_3	USP17L21 USP17L12 USP28 USP43 USP42	2.27e-04	72	143	5	PS50235
Domain	USP_dom	USP17L21 USP17L12 USP28 USP43 USP42	2.27e-04	72	143	5	IPR028889
Domain	Peptidase_C19_UCH	USP17L21 USP17L12 USP28 USP43 USP42	2.27e-04	72	143	5	IPR001394
Domain	WD40_repeat	WDR64 LRRK2 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 WDR72	2.52e-04	272	143	9	IPR001680
Domain	ConA-like_dom	COL12A1 COL20A1 CMYA5 ITGB4 ADGRG4 NRXN3 EGFLAM USH2A	2.88e-04	219	143	8	IPR013320
Domain	WD_REPEATS_1	WDR64 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 RIC1 WDR72	2.96e-04	278	143	9	PS00678
Domain	WD_REPEATS_2	WDR64 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 RIC1 WDR72	3.03e-04	279	143	9	PS50082
Domain	WD_REPEATS_REGION	WDR64 EDC4 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 RIC1 WDR72	3.03e-04	279	143	9	PS50294
Domain	VWFA	COL12A1 COL20A1 ITGAE ITGB2 ITGB4	4.17e-04	82	143	5	PS50234
Domain	VWA	COL12A1 COL20A1 ITGAE ITGB2 ITGB4	4.66e-04	84	143	5	SM00327
Domain	SEA	MUC16 TMPRSS11F MUC3A	6.96e-04	23	143	3	PS50024
Domain	SEA_dom	MUC16 TMPRSS11F MUC3A	6.96e-04	23	143	3	IPR000082
Domain	-	COL12A1 ADGRG4 NRXN3 EGFLAM USH2A	8.18e-04	95	143	5	2.60.120.200
Domain	Kinesin_assoc	KIF1A KIF14	8.56e-04	6	143	2	PF16183
Domain	GAR	GAS2L3 MACF1	8.56e-04	6	143	2	PS51460
Domain	GAS2	GAS2L3 MACF1	8.56e-04	6	143	2	PF02187
Domain	Kinesin_assoc	KIF1A KIF14	8.56e-04	6	143	2	IPR032405
Domain	-	GAS2L3 MACF1	8.56e-04	6	143	2	3.30.920.20
Domain	GAS_dom	GAS2L3 MACF1	8.56e-04	6	143	2	IPR003108
Domain	GAS2	GAS2L3 MACF1	8.56e-04	6	143	2	SM00243
Domain	FN3	COL12A1 COL20A1 CMYA5 ITGB4 ATF7IP EGFLAM USH2A	8.65e-04	199	143	7	PS50853
Domain	VWF_A	COL12A1 COL20A1 ITGAE ITGB2 ITGB4	9.85e-04	99	143	5	IPR002035
Domain	FN3_dom	COL12A1 COL20A1 CMYA5 ITGB4 ATF7IP EGFLAM USH2A	1.15e-03	209	143	7	IPR003961
Domain	Integrin_B_tail	ITGB2 ITGB4	1.19e-03	7	143	2	SM01242
Domain	Integrin_bsu_tail	ITGB2 ITGB4	1.19e-03	7	143	2	IPR012896
Domain	Integrin_B_tail	ITGB2 ITGB4	1.19e-03	7	143	2	PF07965
Domain	fn3	COL12A1 COL20A1 CMYA5 ITGB4 EGFLAM USH2A	1.56e-03	162	143	6	PF00041
Domain	INB	ITGB2 ITGB4	1.58e-03	8	143	2	SM00187
Domain	Integrin_bsu_VWA	ITGB2 ITGB4	1.58e-03	8	143	2	IPR002369
Domain	Integrin_beta	ITGB2 ITGB4	1.58e-03	8	143	2	PF00362
Domain	-	LRRK2 PSMD2 HEATR5A ARMCX2 HEATR6 MRO MED12	1.63e-03	222	143	7	1.25.10.10
Domain	Actin	ACTL6A ACTL6B ACTL9	1.69e-03	31	143	3	IPR004000
Domain	Actin	ACTL6A ACTL6B ACTL9	1.69e-03	31	143	3	PF00022
Domain	ACTIN	ACTL6A ACTL6B ACTL9	1.69e-03	31	143	3	SM00268
Domain	Integrin_bsu	ITGB2 ITGB4	2.02e-03	9	143	2	IPR015812
Domain	INTEGRIN_BETA	ITGB2 ITGB4	2.02e-03	9	143	2	PS00243
Domain	PSI_integrin	ITGB2 ITGB4	2.02e-03	9	143	2	PF17205
Domain	ZU5	ANK2 ANK3	2.02e-03	9	143	2	SM00218
Domain	Integin_beta_N	ITGB2 ITGB4	2.02e-03	9	143	2	IPR033760
Domain	-	GAS2L3 CEP95 NAV3 MACF1	2.15e-03	71	143	4	1.10.418.10
Domain	-	COL12A1 COL20A1 ITGB2 ITGB4	2.50e-03	74	143	4	3.40.50.410
Domain	ZU5	ANK2 ANK3	2.52e-03	10	143	2	PS51145
Domain	CH-domain	GAS2L3 CEP95 NAV3 MACF1	2.63e-03	75	143	4	IPR001715
Domain	FN3	COL12A1 COL20A1 CMYA5 ITGB4 EGFLAM USH2A	3.04e-03	185	143	6	SM00060
Domain	LAM_G_DOMAIN	NRXN3 EGFLAM USH2A	3.05e-03	38	143	3	PS50025
Domain	Laminin_G_2	NRXN3 EGFLAM USH2A	3.53e-03	40	143	3	PF02210
Domain	ZU5	ANK2 ANK3	3.65e-03	12	143	2	PF00791
Domain	ZU5_dom	ANK2 ANK3	3.65e-03	12	143	2	IPR000906
Domain	WD40	WDR64 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 WDR72	3.85e-03	259	143	7	PF00400
Domain	MIRO-like	LRRK2 NKIRAS2	4.30e-03	13	143	2	IPR013684
Domain	Roc	LRRK2 NKIRAS2	4.30e-03	13	143	2	PF08477
Domain	PSI	ITGB2 ITGB4 SEMA6D	4.63e-03	44	143	3	IPR016201
Domain	LamG	NRXN3 EGFLAM USH2A	4.63e-03	44	143	3	SM00282
Domain	ARM-like	LRRK2 PSMD2 HEATR5A ARMCX2 HEATR6 MRO MED12	4.82e-03	270	143	7	IPR011989
Domain	-	COL12A1 MYCBP2 COL20A1 TMIGD3 CMYA5 ITGB4 IGSF10 LRIG3 ATF7IP EGFLAM USH2A PALLD	5.01e-03	663	143	12	2.60.40.10
Domain	PSI	ITGB2 ITGB4 SEMA6D	5.24e-03	46	143	3	SM00423
Domain	-	MUC16 TMPRSS11F	5.73e-03	15	143	2	3.30.70.960
Domain	PX	ARHGAP32 RPS6KC1 SNX9	6.26e-03	49	143	3	PF00787
Domain	HABP4_PAI-RBP1	USP17L21 USP17L12	6.51e-03	16	143	2	PF04774
Domain	AT_hook	SETBP1 KMT2A	6.51e-03	16	143	2	PF02178
Domain	Actin_CS	ACTL6A ACTL6B	6.51e-03	16	143	2	IPR004001
Domain	HABP4_PAIRBP1-bd	USP17L21 USP17L12	6.51e-03	16	143	2	IPR006861
Domain	PX	ARHGAP32 RPS6KC1 SNX9	6.62e-03	50	143	3	PS50195
Domain	-	ARHGAP32 RPS6KC1 SNX9	7.00e-03	51	143	3	3.30.1520.10
Domain	ACTINS_2	ACTL6A ACTL6B	7.34e-03	17	143	2	PS00432
Domain	Phox	ARHGAP32 RPS6KC1 SNX9	7.39e-03	52	143	3	IPR001683
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	GGA2 TEX2 USP28 NACA MTSS1 DIDO1 BCR PLEKHG5 ANKH ZFYVE28 LRIG3 NRXN3 GTF3C2 INTS2 SETBP1 PCNX1 CACNA1G PADI2	1.79e-11	529	150	18	14621295
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	MYBBP1A LIMA1 ANK3 MYCBP2 DIDO1 ZNF318 ACTL6A EDC4 EMSY TAF3 GTF3C2 PGRMC2 PAK2 KIF14 KMT2A SNX9 PALLD MED12	3.28e-11	549	150	18	38280479
Pubmed	HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis.	TEX2 NACA DIDO1 PIWIL4 PSMD2 ACTL6A EDC4 RAB11FIP1 RFC4 BCR CNTROB ACSL3 PNPT1 MISP ATP2C1 COG1 KIF14 CACNA1G	5.07e-09	754	150	18	35906200
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	MYBBP1A KIF1A MYCBP2 DIDO1 PSMD2 ZNF318 EDC4 ACSL3 PNPT1 UTP18 UBTF KIF14 KMT2A MACF1 SNX9 MED12	2.66e-08	653	150	16	22586326
Pubmed	The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	19801957
Pubmed	Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	20621111
Pubmed	Cytochrome P450 3As gene expression and testosterone 6 beta-hydroxylase activity in human fetal membranes and placenta at full term.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	20118548
Pubmed	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	23143891
Pubmed	Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	33866277
Pubmed	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	20615193
Pubmed	Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	32001245
Pubmed	CYP3A Polymorphism and Chronic Mercury Intoxication.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	32146629
Pubmed	Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	17582393
Pubmed	CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.	CYP3A7 CYP3A4 CYP3A5	7.86e-08	3	150	3	34688813
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	MYBBP1A LIMA1 ANK2 USP28 NACA DIDO1 ZNF318 EDC4 RFC4 EMSY UBTF ATF7IP PGRMC2 PAK2 KMT2A MACF1 SNX9 PALLD	1.29e-07	934	150	18	33916271
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	ATF7 MYBBP1A CETN2 DIDO1 ZNF318 ACTL6A RFC4 EMSY ACSL3 MISP UTP18 UBN1 GTF3C2 CDC40 INTS2 USP42 UBTF TRAM1 H1-0 KMT2A MYBL2	1.91e-07	1294	150	21	30804502
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ARHGAP32 MYBBP1A LIMA1 ANK2 ANK3 MYCBP2 USP28 DIDO1 CNKSR2 ZNF318 EDC4 BCR EMSY KCNB1 ATF7IP PAK2 MACF1 FOXG1	2.02e-07	963	150	18	28671696
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	ARHGAP32 LIMA1 MYCBP2 TEX2 EXPH5 USP43 EDC4 RAB11FIP1 BCR DENND4C CEP112 CEP95 MAP3K9 KIF14 KMT2A MACF1 PALLD	2.11e-07	861	150	17	36931259
Pubmed	Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.	CYP3A7 CYP3A4 CYP3A5	3.14e-07	4	150	3	34689350
Pubmed	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.	CYP3A7 CYP3A4 CYP3A5	3.14e-07	4	150	3	18978522
Pubmed	Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.	BCR KMT2A AFF1	3.14e-07	4	150	3	34048072
Pubmed	Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.	ZNF318 ACTL6A MCM10 EMSY ZNF518A UBN1 UBTF H1-0 MYBL2	5.69e-07	222	150	9	37071664
Pubmed	Cytochrome P450 isoforms are differently up-regulated in aflatoxin B₁-exposed human lymphocytes and monocytes.	CYP3A7 CYP3A4 CYP3A5	7.81e-07	5	150	3	24168324
Pubmed	Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene.	CYP3A7 CYP3A4 CYP3A5	7.81e-07	5	150	3	11266076
Pubmed	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.	CYP3A7 CYP3A4 CYP3A5	7.81e-07	5	150	3	11093772
Pubmed	Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol.	CYP3A7 CYP3A4 CYP3A5	7.81e-07	5	150	3	14559847
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	MAP9 MYBBP1A LIMA1 LARP6 ANK2 COL20A1 CETN2 PSMD2 ZNF318 NDUFA7 NKIRAS2 RPS6KC1 ACSL3 UTP18 NRXN3 COG1 CEP112 H1-0 KMT2A MACF1 SNX9	1.10e-06	1442	150	21	35575683
Pubmed	Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome.	MYCBP2 NACA ZNF318 MCM10 NCOA4 EIF4ENIF1 INTS2 MED12 MYBL2	1.17e-06	242	150	9	34011540
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	ARHGAP32 ANK2 ANK3 MYCBP2 TEX2 NACA PSMD2 CNKSR2 EDC4 BCR RPS6KC1 ACSL3 ATP2C1 KCNB1 H1-0 NAV3 MACF1 ACTL6B	2.23e-06	1139	150	18	36417873
Pubmed	MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.	MYBBP1A DIDO1 ZNF318 ACTL6A MCM10 RFC4 EMSY UBTF KMT2A MYBL2	2.38e-06	339	150	10	30415952
Pubmed	The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons.	CYP3A7 CYP3A4 CYP3A5	2.72e-06	7	150	3	11137287
Pubmed	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.	CYP3A7 CYP3A4 CYP3A5	2.72e-06	7	150	3	19842932
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	ARHGAP32 ANK3 PPFIBP2 CNKSR2 EIF4ENIF1 UBN1 CDC40 SETBP1 CCDC87 AFF1 RIC1	2.91e-06	430	150	11	35044719
Pubmed	Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.	LIMA1 PSMD2 ACTL6A MISP INTS2 CEP112 SNX9 PALLD MED12	3.04e-06	272	150	9	31010829
Pubmed	A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins.	PPFIBP2 CNKSR2 ACTL6A RAB11FIP1 NCOA4 DENND4C LRIG3 SPATS2L UBTF PAK2 MACF1 SNX9 MAP4K2 WDR72	3.10e-06	719	150	14	35337019
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	TEX2 EDC4 BCR DENND4C MISP EIF4ENIF1 MACF1 PALLD	3.77e-06	209	150	8	36779422
Pubmed	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.	CYP3A7 CYP3A4 CYP3A5	4.33e-06	8	150	3	20147896
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	MAP9 MYBBP1A ANK3 GAS2L3 TEX2 DIDO1 ZNF318 NCOA4 ITGB4 RPS6KC1 INTS2 CEP112 UBTF MAP3K9 AFF1 MACF1 ANKRD12	4.82e-06	1084	150	17	11544199
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	MYBBP1A LIMA1 MYCBP2 DIDO1 ZNF318 EMSY ACSL3 TAF3 UTP18 UBN1 USP42 KMT2A AFF1 MYBL2	7.17e-06	774	150	14	15302935
Pubmed	Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins.	LIMA1 GAS2L3 LRRK2 DIDO1 MCM10 CNTROB PGRMC2 SNX9	7.61e-06	230	150	8	29513927
Pubmed	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	CYP3A7 CYP3A4 CYP3A5	9.23e-06	10	150	3	12865317
Pubmed	Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.	ARHGAP32 GGA2 ANK3 TEX2 BCR EIF4ENIF1 KIF14 MYBL2	1.43e-05	251	150	8	29778605
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	MYCBP2 ZNF318 BCR DENND4C EIF4ENIF1 GTF3C2 ATF7IP KIF14 MED12 MYBL2	1.48e-05	418	150	10	34709266
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	ATF7 TBC1D9B NACA PSMD2 ACTL6A EDC4 RFC4 ACSL3 ZBP1 UTP18 UBN1 COG1 UBTF TRAM1 PGRMC2 H1-0 KIF14 KMT2A SNX9	1.51e-05	1440	150	19	30833792
Pubmed	The PHLPP1 N-Terminal Extension Is a Mitotic Cdk1 Substrate and Controls an Interactome Switch.	MYBBP1A LIMA1 NACA DIDO1 ZNF318 DENND4C MISP EIF4ENIF1	1.65e-05	256	150	8	33397691
Pubmed	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.	CYP3A7 CYP3A4 CYP3A5	1.68e-05	12	150	3	15319333
Pubmed	Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.	CYP3A4 CYP3A5	1.85e-05	2	150	2	27225724
Pubmed	Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7.	CYP3A7 CYP3A4	1.85e-05	2	150	2	28986474
Pubmed	MicroRNA-mediated switching of chromatin-remodelling complexes in neural development.	ACTL6A ACTL6B	1.85e-05	2	150	2	19561591
Pubmed	The combination of CYP3A422 and CYP3A53 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.	CYP3A4 CYP3A5	1.85e-05	2	150	2	28704257
Pubmed	Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.	CYP3A4 CYP3A5	1.85e-05	2	150	2	15900284
Pubmed	Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer.	CYP3A4 CYP3A5	1.85e-05	2	150	2	36688864
Pubmed	Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.	CYP3A4 CYP3A5	1.85e-05	2	150	2	15900215
Pubmed	Homozygous and heterozygous disruptions of ANK3: at the crossroads of neurodevelopmental and psychiatric disorders.	ANK3 ANKH	1.85e-05	2	150	2	23390136
Pubmed	Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.	CYP3A4 CYP3A5	1.85e-05	2	150	2	31309254
Pubmed	Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.	CYP3A4 CYP3A5	1.85e-05	2	150	2	19343327
Pubmed	The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.	KMT2A AFF1	1.85e-05	2	150	2	16169901
Pubmed	CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.	CYP3A4 CYP3A5	1.85e-05	2	150	2	19907160
Pubmed	CYP3A41G and CYP3A53 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation .	CYP3A4 CYP3A5	1.85e-05	2	150	2	27841150
Pubmed	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry.	CYP3A4 CYP3A5	1.85e-05	2	150	2	33512723
Pubmed	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.	CYP3A4 CYP3A5	1.85e-05	2	150	2	30166405
Pubmed	Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.	CYP3A4 CYP3A5	1.85e-05	2	150	2	23459029
Pubmed	CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.	CYP3A4 CYP3A5	1.85e-05	2	150	2	25976223
Pubmed	The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.	CYP3A4 CYP3A5	1.85e-05	2	150	2	33886687
Pubmed	Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.	CYP3A4 CYP3A5	1.85e-05	2	150	2	30926609
Pubmed	Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.	CYP3A4 CYP3A5	1.85e-05	2	150	2	25385241
Pubmed	CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population.	CYP3A4 CYP3A5	1.85e-05	2	150	2	15698606
Pubmed	CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.	CYP3A4 CYP3A5	1.85e-05	2	150	2	14504207
Pubmed	Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers.	CYP3A7 CYP3A4	1.85e-05	2	150	2	26772622
Pubmed	Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.	CYP3A4 CYP3A5	1.85e-05	2	150	2	14515058
Pubmed	The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.	CYP3A4 CYP3A5	1.85e-05	2	150	2	14515059
Pubmed	Molecular characterization of a rare MLL-AF4 (MLL-AFF1) fusion rearrangement in infant leukemia.	KMT2A AFF1	1.85e-05	2	150	2	17889710
Pubmed	Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?	CYP3A4 CYP3A5	1.85e-05	2	150	2	37759317
Pubmed	Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.	CYP3A4 CYP3A5	1.85e-05	2	150	2	24085358
Pubmed	Recombinant CYP3A417 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A417 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.	CYP3A4 CYP3A5	1.85e-05	2	150	2	15634941
Pubmed	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.	CYP3A4 CYP3A5	1.85e-05	2	150	2	26615671
Pubmed	Drugs as CYP3A probes, inducers, and inhibitors.	CYP3A4 CYP3A5	1.85e-05	2	150	2	18058330
Pubmed	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.	CYP3A4 CYP3A5	1.85e-05	2	150	2	16684709
Pubmed	Two isoforms of a human actin-related protein show nuclear localization and mutually selective expression between brain and other tissues.	ACTL6A ACTL6B	1.85e-05	2	150	2	10380635
Pubmed	CYP3A gene expression in human gut epithelium.	CYP3A7 CYP3A5	1.85e-05	2	150	2	7894497
Pubmed	Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product.	KMT2A AFF1	1.85e-05	2	150	2	7689231
Pubmed	Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.	CYP3A4 CYP3A5	1.85e-05	2	150	2	24484539
Pubmed	Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.	CYP3A4 CYP3A5	1.85e-05	2	150	2	22096084
Pubmed	Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.	KMT2A AFF1	1.85e-05	2	150	2	11930009
Pubmed	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.	CYP3A4 CYP3A5	1.85e-05	2	150	2	24469018
Pubmed	Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5.	CYP3A4 CYP3A5	1.85e-05	2	150	2	29475834
Pubmed	Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.	CYP3A4 CYP3A5	1.85e-05	2	150	2	24989928
Pubmed	Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair.	KMT2A AFF1	1.85e-05	2	150	2	34575904
Pubmed	CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.	CYP3A7 CYP3A5	1.85e-05	2	150	2	28500872
Pubmed	Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.	CYP3A7 CYP3A4	1.85e-05	2	150	2	25689036
Pubmed	The Prognostic Role of CYP Enzyme in Kidney Transplantation: A Single Centre Experience.	CYP3A4 CYP3A5	1.85e-05	2	150	2	36396462
Pubmed	MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.	KMT2A AFF1	1.85e-05	2	150	2	27856324
Pubmed	Influence of CYP3A53 polymorphism and interaction between CYP3A53 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.	CYP3A4 CYP3A5	1.85e-05	2	150	2	21513075
Pubmed	Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.	CYP3A7 CYP3A4	1.85e-05	2	150	2	27349315
Pubmed	The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(4;11).	KMT2A AFF1	1.85e-05	2	150	2	34489550
Pubmed	A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.	KMT2A AFF1	1.85e-05	2	150	2	16551973
Pubmed	Decision tree-based modeling of androgen pathway genes and prostate cancer risk.	CYP3A4 CYP3A5	1.85e-05	2	150	2	21493872
Pubmed	CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.	CYP3A4 CYP3A5	1.85e-05	2	150	2	26654672
Pubmed	MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.	IMPDH1 MYBL2	1.85e-05	2	150	2	36494680
Pubmed	The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.	KMT2A AFF1	1.85e-05	2	150	2	1423625
Interaction	SFN interactions	ARHGAP32 LIMA1 MYCBP2 TEX2 EXPH5 PPFIBP2 LRRK2 EDC4 RAB11FIP1 BCR DENND4C CEP112 CEP95 H1-0 PAK2 KIF14 KMT2A MACF1 PALLD	5.75e-07	692	145	19	int:SFN
Interaction	WWTR1 interactions	MYBBP1A LIMA1 ANK3 MYCBP2 DIDO1 ZNF318 ACTL6A EDC4 EMSY GTF3C2 PGRMC2 KMT2A SNX9	1.17e-05	422	145	13	int:WWTR1
Interaction	YWHAH interactions	ARHGAP32 LIMA1 MYCBP2 TEX2 EXPH5 PPFIBP2 LRRK2 USP43 PSMD2 EDC4 RAB11FIP1 BCR PLEKHG5 DENND4C CEP112 CEP95 MAP3K9 PAK2 KIF14 KMT2A MACF1 PALLD	1.31e-05	1102	145	22	int:YWHAH
Interaction	KCNA3 interactions	ARHGAP32 MYBBP1A ANK2 ANK3 EXPH5 NACA LRRK2 PSMD2 DENND4C CEP112 CEP95 UBTF PGRMC2 PAK2 KMT2A MACF1 SNX9 PALLD MED12	1.61e-05	871	145	19	int:KCNA3
Interaction	MCM2 interactions	ANK3 NACA MUC16 PSMD2 ZNF318 ACTL6A MCM10 CMYA5 BCR ACSL3 TAF3 SPATS2L UBN1 GTF3C2 H1-0 KIF14 KMT2A MACF1 SNX9 PALLD MED12	3.14e-05	1081	145	21	int:MCM2
Interaction	YWHAB interactions	ARHGAP32 LIMA1 MYCBP2 EXPH5 LRRK2 USP43 RAB11FIP1 BCR ITGB2 PLEKHG5 ITGB4 DENND4C TBC1D22A CEP112 CEP95 MAP3K9 PAK2 KIF14 KMT2A MACF1	3.99e-05	1014	145	20	int:YWHAB
Cytoband	7q21.1	CYP3A4 CYP3A5	2.93e-04	8	150	2	7q21.1
Cytoband	Ensembl 112 genes in cytogenetic band chr20q13	COL20A1 DIDO1 ZBP1 SYCP2 TP53TG5 KCNB1 MYBL2	5.03e-04	422	150	7	chr20q13
Cytoband	Ensembl 112 genes in cytogenetic band chr17q23	TEX2 HEATR6 INTS2 CEP95	6.70e-04	120	150	4	chr17q23
Cytoband	Ensembl 112 genes in cytogenetic band chr7q22	CYP3A7 CYP3A4 CYP3A5 ACTL6B MUC3A	7.97e-04	219	150	5	chr7q22
Cytoband	Ensembl 112 genes in cytogenetic band chr17p13	MYBBP1A SPEM3 USP43 ITGAE CNTROB XAF1	1.01e-03	346	150	6	chr17p13
GeneFamily	Cytochrome P450 family 3	CYP3A7 CYP3A4 CYP3A5	7.97e-06	8	96	3	1002
GeneFamily	Fibronectin type III domain containing	COL12A1 COL20A1 CMYA5 ITGB4 ATF7IP EGFLAM USH2A	2.30e-05	160	96	7	555
GeneFamily	WD repeat domain containing	WDR64 DMXL1 UTP18 GTF3C2 CDC40 WDSUB1 WDR72	4.93e-04	262	96	7	362
GeneFamily	CD molecules\|Integrin beta subunits	ITGB2 ITGB4	9.80e-04	9	96	2	1159
Coexpression	GSE9006_TYPE_1_VS_TYPE_2_DIABETES_PBMC_AT_DX_DN	EXPH5 ZNF318 EMSY DENND4C SPATS2L CDC40 GUCY1A1 PCNX1 XAF1	2.18e-06	199	149	9	M5799
Coexpression	GSE3400_UNTREATED_VS_IFNB_TREATED_MEF_UP	TBC1D9B GAS2L3 DENND4C DMXL1 ATP2C1 HEATR6 CDC40 WDSUB1	1.59e-05	194	149	8	M6133
Coexpression	GSE22935_WT_VS_MYD88_KO_MACROPHAGE_48H_MBOVIS_BCG_STIM_UP	CYP3A7 FAM120AOS NDUFA7 ITGB4 ANKH SEMA6D PADI2 PALLD	1.91e-05	199	149	8	M7766
Coexpression	GSE3982_EOSINOPHIL_VS_MAC_DN	LIMA1 ACTL6A NKIRAS2 DMXL1 UTP18 TTC23 PGRMC2 IQCG	1.91e-05	199	149	8	M5403
Coexpression	HOEBEKE_LYMPHOID_STEM_CELL_UP	UBR2 NACA LPIN1 SETBP1 MACF1 PALLD	1.97e-05	97	149	6	M14698
Coexpression	DURCHDEWALD_SKIN_CARCINOGENESIS_DN	ANK3 SQLE RAB11FIP1 ATP2C1 SEMA6D CDC40 ATF7IP MACF1 SNX9	2.19e-05	265	149	9	M1684
Coexpression	DURCHDEWALD_SKIN_CARCINOGENESIS_DN	ANK3 SQLE RAB11FIP1 ATP2C1 SEMA6D CDC40 ATF7IP MACF1 SNX9	2.69e-05	272	149	9	MM1027
Coexpression	HE_LIM_SUN_FETAL_LUNG_C6_MUC16_POS_CILIATED_CELL	LARP6 MUC16 ITGB4 PZP PALLD	2.77e-05	62	149	5	M45790
Coexpression	MURARO_PANCREAS_BETA_CELL	TBC1D9B KIF1A MYCBP2 EXPH5 MTSS1 ZNF318 RAB11FIP1 NCOA4 ANKH LPIN1 SEMA6D UBN1 SETBP1 PGRMC2 AFF1 ANKRD12 SNX9	2.85e-05	946	149	17	M39169
Coexpression	LAKE_ADULT_KIDNEY_C2_PODOCYTES	EXPH5 MTSS1 CMYA5 SPATS2L CEP112 MACF1 ANKRD12 PALLD	3.01e-05	212	149	8	M39221
CoexpressionAtlas	dev gonad_e13.5_M_GermCell_Oct_top-relative-expression-ranked_1000	MYBBP1A TEX2 USP28 PIWIL4 PSMD2 HEATR5A ZNF318 MCM10 ZNF518A ACSL3 PNPT1 SYCP2 UTP18 CEP95 KIF14 ANKRD12 WDSUB1 MYBL2 IQCG	2.47e-06	810	144	19	gudmap_dev gonad_e13.5_M_GermCell_Oct_1000
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAP9 MTSS1 ZNF318 RAB11FIP1 ATF7IP AFF1 SNX9 FAM83A	2.38e-07	189	148	8	b13f315f617840eb5143a4e8a33a657c20365c21
ToppCell	(7)_Epithelial_cells-(7)_Epithelial-I_(AT1)\|(7)_Epithelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4)	COL12A1 NCKAP5 CNKSR2 RAB11FIP1 MISP SEMA6D FAM167A PALLD	3.53e-07	199	148	8	5a002d49a8b84c158f7b4d7a3e78e6a937757bb7
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M\|organoid_Kanton_Nature / Sample Type, Dataset, Time_group, and Cell type.	LIMA1 KIF1A MYCBP2 MTSS1 SEMA6D ACTL6B ANKRD12 FOXG1	3.53e-07	199	148	8	b2d7dea11207cca63d688f8051143850b29dbdf0
ToppCell	control-Epithelial\|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ARHGAP32 LIMA1 ANK3 EXPH5 MUC16 RAB11FIP1 H1-0 PALLD	3.67e-07	200	148	8	f95bbb94e51ac28b1995026c599ec3a34e012916
ToppCell	AT1_cells-HP_01\|World / lung cells shred on cell class, cell subclass, sample id	COL12A1 NCKAP5 CNKSR2 MISP SEMA6D FAM167A MUC3A	2.09e-06	176	148	7	458720776b0151cd55acc352d509599cb62f0ca8
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL12A1 ANK3 GAS2L3 COL20A1 CNKSR2 ITGB4 CCDC87	2.61e-06	182	148	7	812ff2a50a510b18d865e89465dba1754a08ef61
ToppCell	droplet-Lung-nan-18m-Mesenchymal-pulmonary_interstitial_fibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LARP6 S1PR3 IGSF10 GUCY1A1 CEP112 CACNA1G PALLD	3.01e-06	186	148	7	b58db5abdd3e9f0214b198c3cbd09b0b3c321eab
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	GGA2 PPFIBP2 MTSS1 RAB11FIP1 SETBP1 FAM167A MYBL2	3.01e-06	186	148	7	55b239834b96b1f7787ec77a7d19796d617bbbf0
ToppCell	droplet-Lung-nan-18m-Mesenchymal-Myofibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LARP6 S1PR3 IGSF10 GUCY1A1 CEP112 CACNA1G PALLD	3.01e-06	186	148	7	cd6502bbf9dce318fdbb4965d49df8951e5f795c
ToppCell	AT1_cells-SSc-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	COL12A1 ANK2 NCKAP5 CNKSR2 RAB11FIP1 MISP MUC3A	3.12e-06	187	148	7	f1dda349335e08dbfc8395d373924037f5ad2fd6
ToppCell	-Unknown-Endothelial-Myofibroblast\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 PPFIBP2 LRRK2 LYRM2 ATF7IP KMT2A PALLD	3.23e-06	188	148	7	6468fa95ad0395395301115286f2d8c0df5d3882
ToppCell	-Unknown-Endothelial\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 PPFIBP2 LRRK2 LYRM2 ATF7IP KMT2A PALLD	3.23e-06	188	148	7	7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6
ToppCell	-Unknown\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 PPFIBP2 LRRK2 LYRM2 ATF7IP KMT2A PALLD	3.23e-06	188	148	7	9cb718bfe1358c6fd842f096e228eb0abb9aefc6
ToppCell	droplet-Spleen-nan-18m-Lymphocytic-B_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GGA2 MYCBP2 MTSS1 LRRK2 ZNF318 MACF1 SNX9	3.47e-06	190	148	7	ee7b60cdf93c695ea2d59a170ca8cf4dc93e7eb2
ToppCell	AT1_cells-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	COL12A1 NCKAP5 CNKSR2 RAB11FIP1 MISP SEMA6D FAM167A	4.40e-06	197	148	7	80d81be244c94c435accb643449b4ce6a3462c7f
ToppCell	ASK440-Epithelial-Type_1\|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq	COL12A1 EXPH5 NCKAP5 CNKSR2 RAB11FIP1 SEMA6D FAM167A	4.40e-06	197	148	7	1eda2c2504451a3d626dda5c2b2b12eeaa6bca54
ToppCell	ASK440-Epithelial-Type_1\|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq	COL12A1 NCKAP5 CNKSR2 RAB11FIP1 SEMA6D TRAM1 FAM167A	4.40e-06	197	148	7	782449c522c9e16e72bf999a73090688a3aefe06
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ANK2 MYCBP2 S1PR3 IGSF10 MACF1 PZP PALLD	4.70e-06	199	148	7	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	NS-control-d_0-4-Epithelial\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ARHGAP32 ANK3 EXPH5 MUC16 ITGB4 H1-0 PALLD	4.86e-06	200	148	7	d014959891893b6d3854a471fba1dc50c6625a0a
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	UBR2 MYCBP2 ATF7IP KMT2A MACF1 XAF1 ANKRD12	4.86e-06	200	148	7	12f1685ce8f218433068e090c9d839cd5a1910bf
ToppCell	NS-control\|NS / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ARHGAP32 LIMA1 ANK3 EXPH5 MUC16 ITGB4 PALLD	4.86e-06	200	148	7	ecbe89ff95d046155b984c8c150e0b9e7278f839
ToppCell	COVID-19_Mild\|World / 5 Neutrophil clusters in COVID-19 patients	ANK3 LRRK2 CCDC168 LRIG3 PCNX1 XAF1	1.20e-05	152	148	6	2ff0980dfd8d430cca14649151d856edef115720
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	KIF1A GAS2L3 MCM10 RFC4 KIF14 MYBL2	2.04e-05	167	148	6	50c29ea660bf07b890e4ac1a1985d0761d863dee
ToppCell	Control\|World / group, cell type (main and fine annotations)	ANK3 CYP3A5 EXPH5 NCKAP5 RAB11FIP1 NRXN3	2.11e-05	168	148	6	a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCell	COVID-19-Heart-Neuronal\|Heart / Disease (COVID-19 only), tissue and cell type	ANK2 ANK3 GAS2L3 ITGB4 NRXN3 SEMA6D	2.49e-05	173	148	6	6fb5f9e6536a5d57fd8e6657b494047a2d0bc9c7
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	COL12A1 LRRK2 USP43 CNKSR2 CCDC168 SEMA6D	2.57e-05	174	148	6	b3cd22e717d178269e6d5bd5ed7b2d945cd8ea25
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CMYA5 IGSF10 GUCY1A1 CEP112 ATF7IP MACF1	2.74e-05	176	148	6	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma\|TCGA-Brain / Sample_Type by Project: Shred V9	KIF1A BCR TAF3 KCNB1 KMT2A ANKRD12	2.83e-05	177	148	6	e8ab340b20cd41554c3841fe980e078e878af35f
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ARHGAP32 ANK3 MUC16 CMYA5 RAB11FIP1 MACF1	3.01e-05	179	148	6	6e965e424eebef50f0202cff75f458be395cfca1
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL12A1 ANK3 COL20A1 CNKSR2 ITGB4 CCDC87	3.11e-05	180	148	6	d9c9399df3e2d9f23dbbfffb6cbe8404bf01e2b7
ToppCell	droplet-Liver-LIVER_HEP-30m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYCBP2 LRRK2 IGSF10 KCNB1 KMT2A MACF1	3.11e-05	180	148	6	dd1b10c7f5a0fbc63163844ca1882884a24a84d3
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Neuronal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL12A1 ANK3 COL20A1 CNKSR2 ITGB4 CCDC87	3.11e-05	180	148	6	dad458398683ff80a6e207bdc08e257d1bb757d6
ToppCell	droplet-Liver-LIVER_HEP\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYCBP2 LRRK2 IGSF10 KCNB1 KMT2A MACF1	3.11e-05	180	148	6	423454e3390080ae03bb3cbb267255ebfe4df080
ToppCell	PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK2 PPFIBP2 CYSLTR1 S1PR3 GUCY1A1 MYBL2	3.20e-05	181	148	6	274c0b768925cd5804483303f8c5ebd17a534c41
ToppCell	pdx-Tumor_cells-T6\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	ANKH LPIN1 NRXN3 SETBP1 EGFLAM PADI2	3.30e-05	182	148	6	7b24a4f712e1ae1525e8f1c8ec4e1fc43489cbee
ToppCell	343B-Epithelial_cells-Epithelial-I_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COL12A1 NCKAP5 RAB11FIP1 SEMA6D FAM167A PALLD	3.51e-05	184	148	6	c7073d1b2c4fdb154d87678b92a0629c02116972
ToppCell	343B-Epithelial_cells-Epithelial-I_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COL12A1 NCKAP5 RAB11FIP1 SEMA6D FAM167A PALLD	3.51e-05	184	148	6	1ed558a88215b248431c524ea16f13d9022ae98c
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell-pulmonary_interstitial_myofibroblast\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LARP6 S1PR3 IGSF10 GUCY1A1 CACNA1G PALLD	3.84e-05	187	148	6	8bd635abdee5d5a12a3f7bf74eab4282e8e40741
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LARP6 S1PR3 IGSF10 GUCY1A1 CACNA1G PALLD	3.84e-05	187	148	6	3cb8cd7f7a4306ff74d1f7f9964014008ec1c6a0
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	ATP2C1 ATF7IP KMT2A MACF1 PCNX1 ANKRD12	3.96e-05	188	148	6	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1-AT1_L.0.5.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL12A1 NCKAP5 SEMA6D TRAM1 FAM167A MUC3A	3.96e-05	188	148	6	e9cef856a96a97afac5ecafe2ee91eff0d731e01
ToppCell	T_cells-ISG-high_CD4+_T_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	ANK3 ZBP1 PNPT1 SPATS2L AFF1 XAF1	3.96e-05	188	148	6	6f8946d4710f6e32c937213f99b790b098b8819c
ToppCell	E16.5-samps-Mesenchymal\|E16.5-samps / Age Group, Lineage, Cell class and subclass	S1PR3 GUCY1A1 MACF1 CACNA1G EGFLAM PALLD	3.96e-05	188	148	6	3f0f662be684e3a4c6652e636cc135a39a1d2790
ToppCell	droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l32-30\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ANK3 KIF1A COL20A1 CNKSR2 ITGB4 MRO	3.96e-05	188	148	6	502045a39ffb1e92bd9499848368e8fa971edb88
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|RV / Chamber and Cluster_Paper	ANK2 ANK3 NCKAP5 CMYA5 ANKH PALLD	4.20e-05	190	148	6	93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b
ToppCell	P03-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	CYSLTR1 ARMCX2 BCR S1PR3 GUCY1A1 EGFLAM	4.20e-05	190	148	6	979b1476fd2692fde977ce56257315fcfc8a01d5
ToppCell	LAM-Epithelial-AT1\|Epithelial / Condition, Lineage and Cell class	COL12A1 NCKAP5 RAB11FIP1 MISP FAM167A PALLD	4.32e-05	191	148	6	3457e15d1e9b36a78363d46b320c4ec46b40290a
ToppCell	(04)_Pre-ciliated\|World / shred by cell type and Timepoint	MAP9 USP43 HEATR5A CNTROB CCDC87 IQCG	4.32e-05	191	148	6	37cf121e6e80760c8519075b7845b9029958a988
ToppCell	LA-03._Atrial_Cardiomyocyte\|LA / Chamber and Cluster_Paper	ANK2 ANK3 USP28 NCKAP5 CMYA5 PALLD	4.32e-05	191	148	6	5d1b674eb7703830b7ce8bbeac3363cabd0e6ae9
ToppCell	droplet-Trachea-3m-Epithelial-airway_epithelial-neuroendocrine_cell-neuroendocrine\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CNKSR2 S1PR3 SEMA6D GUCY1A1 EGFLAM PALLD	4.32e-05	191	148	6	72f1ddc09080dbfea8d51294cbf7f9d4925f9cc0
ToppCell	droplet-Trachea-3m-Epithelial-airway_epithelial-neuroendocrine_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CNKSR2 S1PR3 SEMA6D GUCY1A1 EGFLAM PALLD	4.32e-05	191	148	6	6e7f589efc997f32175e0789c5ea7ca46e1389b8
ToppCell	droplet-Trachea-nan-3m-Epithelial-neuroendocrine_cell\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CNKSR2 S1PR3 SEMA6D GUCY1A1 EGFLAM PALLD	4.32e-05	191	148	6	3ce403e0beedb544edeb3ae6eb30267040d00c21
ToppCell	P07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)\|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	CYSLTR1 ARMCX2 BCR S1PR3 GUCY1A1 EGFLAM	4.32e-05	191	148	6	2ad717b59215ad8d933e9637d363b65d7298e5d4
ToppCell	PCW_07-8.5-Epithelial-Epithelial_proliferating-epi_proliferating2_(13)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	EXPH5 USP43 NRXN3 MAP3K9 KIF14 WDR72	4.45e-05	192	148	6	25378b5e4b0cea8415ff125783511fc25a56fc00
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	LIMA1 COL12A1 ANK2 IGSF10 SETBP1 NAV3	4.45e-05	192	148	6	8d56e360ebc624ca4cd7f0af4f3cc599c244f134
ToppCell	facs-Pancreas-Endocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIF1A EXPH5 SQLE ANKH DENND4C USH2A	4.45e-05	192	148	6	5b7093d5af5ae7b0e6d3a464cc56272440ecedad
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	ANK3 NCKAP5 TBC1D22A SETBP1 MACF1 WDR72	4.45e-05	192	148	6	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	SQLE MTSS1 RAB11FIP1 SETBP1 SNX9 MYBL2	4.58e-05	193	148	6	08696a99309f5b088692ddac8cca35413b5e810d
ToppCell	Neuron-Postmitotic-Inhibitory_Neuron-SST-MGE1-4\|World / Primary Cells by Cluster	GAS2L3 MYCBP2 NACA MTSS1 NRXN3 ANKRD12	4.58e-05	193	148	6	2eb6e4cff4fe3ce564c1581f6f7df4834895aaa9
ToppCell	NS-moderate-d_0-4\|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ANK3 EXPH5 MTSS1 SPAG8 IGSF10 PZP	4.58e-05	193	148	6	ea345d34440b25f65358a53dc72831998d1c3620
ToppCell	10x5'v1-week_17-19-Mesenchymal_osteo-stroma-early_osteoblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	COL12A1 ANKH SEMA6D NAV3 EGFLAM WDR72	4.58e-05	193	148	6	5e46a9f65e85aca78f825fdef88a95b97eec8743
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ANK3 CYP3A5 PPFIBP2 CMYA5 RAB11FIP1 ITGB4	4.58e-05	193	148	6	a5695ce2e24a62026ae28f3dea07ca4a435206b8
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-SMC_prolif-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	COL12A1 S1PR3 SPATS2L GUCY1A1 KIF14 EGFLAM	4.72e-05	194	148	6	78dcb9d48259afabe73b41c5508a73a8d62339a4
ToppCell	RA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	ANK2 ANK3 USP28 NCKAP5 CMYA5 PALLD	4.72e-05	194	148	6	89812fb164065041357bb37a3c2d87028ec3de4e
ToppCell	RA-03._Atrial_Cardiomyocyte\|RA / Chamber and Cluster_Paper	ANK2 ANK3 USP28 NCKAP5 CMYA5 PALLD	4.72e-05	194	148	6	c3535f7cc0076653c72db582047cff053c322397
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-goblet\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ARHGAP32 EXPH5 MISP SPATS2L H1-0 PADI2	4.85e-05	195	148	6	c5f33b420c9ac14dc67fea632b8c2bc2442cbf3d
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAP9 GGA2 MTSS1 RAB11FIP1 SETBP1 SNX9	4.85e-05	195	148	6	481989d2e5bd2582da3d86b0155c4d6615317067
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAP9 GGA2 MTSS1 RAB11FIP1 SETBP1 SNX9	4.85e-05	195	148	6	6108a27523d1b93a7fbe35cb95704a5ad9071e3c
ToppCell	356C-Lymphocytic-CD4_T-cell-Proliferating_T_cell\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	MCM10 IGSF10 GUCY1A1 H1-0 KIF14 MYBL2	4.85e-05	195	148	6	751cb00b0f3005be6b645adadfbb9dd2215b6e08
ToppCell	normal_Lung-Epithelial_cells-AT1\|normal_Lung / Location, Cell class and cell subclass	COL12A1 NCKAP5 RAB11FIP1 MISP SEMA6D FAM167A	4.85e-05	195	148	6	569d1ebc5a5aa110a2430b096755ae35354040c4
ToppCell	AT1_cells\|World / lung cells shred on cell class, cell subclass, sample id	COL12A1 NCKAP5 RAB11FIP1 MISP SEMA6D FAM167A	4.85e-05	195	148	6	792d6a49b0a875a00569071183d195287a9925c5
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYCBP2 CMYA5 IGSF10 ACSL3 GUCY1A1 CEP112	4.85e-05	195	148	6	5c86fddd6d0530beecf45ea5ba6b823123847696
ToppCell	ILEUM-non-inflamed-(9)_Enteric_neurons\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	ANK2 ANK3 GAS2L3 ITGB4 NRXN3 SEMA6D	4.99e-05	196	148	6	998aa523555ed6bc9c1b5cacbf7ba77c7b218e6b
ToppCell	Epithelial_cells-AT1_cells\|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id	COL12A1 NCKAP5 CNKSR2 RAB11FIP1 SEMA6D FAM167A	4.99e-05	196	148	6	6c99d29162848161c1f166a032320f87a5d5a631
ToppCell	ILEUM-non-inflamed-(9)_Neuro_cell\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	ANK2 ANK3 GAS2L3 ITGB4 NRXN3 SEMA6D	4.99e-05	196	148	6	2b08cd6730119d5dea0152709ab8de580b66cd3c
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ANK2 IGSF10 SETBP1 NAV3 MACF1 PALLD	5.14e-05	197	148	6	94a9603cbd3516fbcce871909693b88f20d41713
ToppCell	PND03-Mesenchymal\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	S1PR3 SPATS2L GUCY1A1 MACF1 EGFLAM PALLD	5.14e-05	197	148	6	e3053ef8f604b6892c21c03e12612b49d3d30f23
ToppCell	356C-Epithelial_cells-Epithelial-I_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COL12A1 NCKAP5 RAB11FIP1 MISP SEMA6D FAM167A	5.14e-05	197	148	6	69d5b8588046d119b5dff9a7fd6f49e97e00a5b7
ToppCell	356C-Epithelial_cells-Epithelial-I_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COL12A1 NCKAP5 RAB11FIP1 MISP SEMA6D FAM167A	5.14e-05	197	148	6	e6cbfa267eb2e05b441fd034786faae07bb0e081
ToppCell	TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Ductal_Carcinoma\|TCGA-Breast / Sample_Type by Project: Shred V9	SQLE PSMD2 ACTL6A MCM10 KIF14 MYBL2	5.28e-05	198	148	6	880f9817f5145f10f29fc05c5866090433532fe2
ToppCell	3'-Adult-Distal_Rectal-Epithelial-epithelial_progenitor_cell-TA\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LIMA1 CYP3A5 SQLE MISP ANKRD12 PADI2	5.28e-05	198	148	6	1fbec311f2c987ca90a023a5989128c05aa12d5c
ToppCell	3'-Adult-Distal_Rectal-Epithelial-epithelial_progenitor_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LIMA1 CYP3A5 SQLE MISP ANKRD12 PADI2	5.28e-05	198	148	6	4f26a60e99f42343e5af7221723e108a1a1b7827
ToppCell	Epithelial_cells-AT1-AT2_cells\|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id	COL12A1 NCKAP5 RAB11FIP1 MISP FAM167A PALLD	5.28e-05	198	148	6	fbc46b20bcd44f2083170aacbc6f5dd00fba685c
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	UBR2 ANK3 LPIN1 ATF7IP MACF1 ANKRD12	5.43e-05	199	148	6	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	severe-B_intermediate\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	GGA2 ANK2 MTSS1 DMXL1 SETBP1 SNX9	5.43e-05	199	148	6	17283d75a2a900369f63ed02996e7ede97f46140
ToppCell	COVID-19-COVID-19_Mild-Myeloid-immature_Neutrophil\|COVID-19_Mild / Disease, condition lineage and cell class	CCDC168 MCM10 IGSF10 H1-0 KIF14 MYBL2	5.43e-05	199	148	6	e222b90caf45904d8f763574e7b6aac13333df92
ToppCell	(02)_MMP9/10+-(2)_GFP_FOXI1\|(02)_MMP9/10+ / shred by cell type by condition	LIMA1 SPATS2L PGRMC2 XAF1 ANKRD12 PALLD	5.43e-05	199	148	6	18a7f9ced4364f45b184bd529f32ef02c27779d3
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ANK2 S1PR3 IGSF10 MACF1 PZP PALLD	5.43e-05	199	148	6	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	TCGA-Stomach-Primary_Tumor\|TCGA-Stomach / Sample_Type by Project: Shred V9	ACTL6A RFC4 LRRC8D UTP18 KIF14 MYBL2	5.43e-05	199	148	6	38f1f612b29feb868322999ceeda78e52447ec4f
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma\|TCGA-Stomach / Sample_Type by Project: Shred V9	ACTL6A RFC4 LRRC8D UTP18 KIF14 MYBL2	5.43e-05	199	148	6	b10698aee2e6c17bc559eb4f723024141f914b90
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ARHGAP32 ANK3 SQLE LRRK2 NRXN3 PADI2	5.58e-05	200	148	6	e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae
ToppCell	mild-CD8+_Tem\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP28 ZBP1 KMT2A MACF1 XAF1 PZP	5.58e-05	200	148	6	d8aec4904c9420b8f9d7508658ba1e36c66cdfcc
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ANK2 S1PR3 IGSF10 MACF1 PZP PALLD	5.58e-05	200	148	6	b79628fd1386aa9a3b0e9fa81def0bc100c3c073
ToppCell	control\|World / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ARHGAP32 LIMA1 ANK3 EXPH5 ITGB4 PALLD	5.58e-05	200	148	6	97f36d2c197e03d93a1fc59949d77ae90f6e6a9a
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ANK2 S1PR3 IGSF10 MACF1 PZP PALLD	5.58e-05	200	148	6	50ca6550998e461ef26dd670351060bd940765a8
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	CNKSR2 IGSF10 SETBP1 NAV3 MACF1 PALLD	5.58e-05	200	148	6	aa1a35dcca3b799241eef4237f6eb94660e019f0
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	ANK3 MYCBP2 CNKSR2 NRXN3 KCNB1 SETBP1	5.58e-05	200	148	6	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ANK2 S1PR3 IGSF10 MACF1 PZP PALLD	5.58e-05	200	148	6	3bdba9612cd7c612b76aa9abecc4a6529aabfc1c
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CNKSR2 IGSF10 SETBP1 NAV3 MACF1 PALLD	5.58e-05	200	148	6	a510deaada669e690329183e18df02870bd204b3
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ANK2 S1PR3 IGSF10 MACF1 PZP PALLD	5.58e-05	200	148	6	44a68bacdb3d5bf563bd35952176995850933a81
Drug	Ramipril [87333-19-5]; Up 200; 9.6uM; PC3; HT_HG-U133A	GGA2 BCR ITGB2 ITGB4 EMSY LPIN1 GUCY1A1 TBC1D22A H1-0 KMT2A	5.44e-07	195	146	10	7144_UP
Drug	Alfentanil	CYP3A7 CYP3A4 CYP3A5	5.09e-06	6	146	3	ctd:D015760
Drug	tetra-zol-3	CYP3A4 CYP3A5 SQLE	1.41e-05	8	146	3	CID000005404
Drug	R7 1	CYP3A4 CYP3A5 SQLE	1.41e-05	8	146	3	CID000001949
Drug	S 840	CYP3A7 CYP3A4 CYP3A5	2.11e-05	9	146	3	CID000096338
Drug	8-bromoguanine	CYP3A7 CYP3A4 ACTL6A ACTL6B FOXG1	2.27e-05	53	146	5	CID000076473
Drug	4-hydroxymidazolam	CYP3A7 CYP3A4 CYP3A5	3.00e-05	10	146	3	CID000124449
Drug	4-hydroxydebrisoquine	CYP3A4 CYP3A5 AFF1	3.00e-05	10	146	3	CID000107669
Drug	2,4-diaminotoluene	GAS2L3 SQLE RFC4 LRRC8D ANKH ACSL3 ZBP1 SEMA6D H1-0	3.20e-05	247	146	9	ctd:C010914
Drug	Dacarbazine [4342-03-4]; Down 200; 22uM; HL60; HG-U133A	GGA2 CYP3A4 ATP2C1 PAK2 AFF1 PCNX1 ANKRD12 MED12	3.86e-05	195	146	8	1762_DN
Drug	Canrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; PC3; HT_HG-U133A	MAP9 SQLE HEATR6 UBN1 GTF3C2 H1-0 B9D1 KMT2A	4.00e-05	196	146	8	2065_DN
Drug	4-hydroxymidazolam	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C042940
Drug	norverapamil	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C016904
Drug	5,6-dihydro-2H-pyran-2-one	CYP3A4 CYP3A5	4.08e-05	2	146	2	CID000520660
Drug	notopterol	CYP3A4 CYP3A5	4.08e-05	2	146	2	CID005320227
Drug	N-acetyl-S--(1,2,3,4,4-pentachlorobutadienyl)cysteine sulfoxide	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C114289
Drug	tazofelone	CYP3A4 ZNF318	4.08e-05	2	146	2	CID000068745
Drug	6 beta-hydroxytestosterone	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C025591
Drug	CQA 206-291	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C059483
Drug	fructus schizandrae, radix ginseng, radix ophiopogonis drug combination	CYP3A4 CYP3A5	4.08e-05	2	146	2	ctd:C009252
Drug	bifonazole	CYP3A4 CYP3A5 SQLE	4.10e-05	11	146	3	CID000002378
Drug	Troleandomycin	CYP3A7 CYP3A4 CYP3A5	4.10e-05	11	146	3	ctd:D014217
Drug	Ticalopride	CYP3A7 CYP3A4 CYP3A5	4.10e-05	11	146	3	CID000216236
Drug	3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A	LARP6 ARMCX2 SEMA6D TBC1D22A PCNX1 MAP4K2 FOXG1 IQCG	4.14e-05	197	146	8	6060_DN
Drug	Fluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A	GGA2 KIF1A ZNF318 ITGB4 SYCP2 GTF3C2 B9D1 MED12	4.14e-05	197	146	8	5356_DN
Drug	Clidinium bromide [3485-62-9]; Down 200; 9.2uM; HL60; HT_HG-U133A	TBC1D9B EXPH5 EMSY LPIN1 SYCP2 UBTF B9D1 PADI2	4.14e-05	197	146	8	2734_DN
Drug	LY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A	MAP9 ARHGAP32 KIF1A EDC4 BCR UBN1 GTF3C2 MED12	4.14e-05	197	146	8	6935_DN
Drug	Norethynodrel [68-23-5]; Down 200; 13.4uM; PC3; HT_HG-U133A	GGA2 ANK3 NACA BCR EIF4ENIF1 GUCY1A1 TBC1D22A NAV3	4.30e-05	198	146	8	1818_DN
Drug	Sulfinpyrazone [57-96-5]; Up 200; 9.8uM; HL60; HG-U133A	ARHGAP32 ANK2 GTF3C2 CDC40 TBC1D22A AFF1 PADI2 MED12	4.30e-05	198	146	8	1574_UP
Drug	Suxibuzone [27470-51-5]; Up 200; 9.2uM; HL60; HT_HG-U133A	ANK3 MISP SYCP2 SEMA6D SETBP1 B9D1 PCNX1 CACNA1G	4.61e-05	200	146	8	2503_UP
Drug	propionanilide	CYP3A7 CYP3A4 CYP3A5	8.93e-05	14	146	3	CID000012107
Drug	7-BFC	CYP3A7 CYP3A4 CYP3A5	8.93e-05	14	146	3	CID000848780
Drug	PD 0325901	CYP3A7 ANK3 CYP3A4 CYP3A5 NAV3 FOXG1	9.47e-05	114	146	6	ctd:C506614
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	SQLE RAB11FIP1 ACSL3 LPIN1 H1-0 MAP3K9 PALLD	1.12e-04	169	146	7	1793_UP
Drug	sterigmatocystin	CYP3A7 CYP3A4 CYP3A5 WDSUB1	1.12e-04	39	146	4	CID005280389
Drug	erythralosamine	CYP3A4 CYP3A5	1.22e-04	3	146	2	CID000352196
Drug	3-methoxymorphinan	CYP3A4 CYP3A5	1.22e-04	3	146	2	ctd:C028657
Drug	dechloroethylcyclophosphamide	CYP3A4 CYP3A5	1.22e-04	3	146	2	ctd:C064445
Drug	6 beta-hydroxydexamethasone	CYP3A4 CYP3A5	1.22e-04	3	146	2	CID000063050
Drug	territrem C	CYP3A4 CYP3A5	1.22e-04	3	146	2	CID000160306
Drug	17-hydroxypregnenolone sulfate	CYP3A7 CYP3A4	1.22e-04	3	146	2	CID000152971
Drug	1-hydroxymethylmidazolam	CYP3A4 CYP3A5	1.22e-04	3	146	2	ctd:C040081
Drug	N-acetyl-S-pentachloro-1,3-butadienylcysteine	CYP3A4 CYP3A5	1.22e-04	3	146	2	ctd:C049739
Drug	1,8-cineole	CYP3A4 CYP3A5 BCR KMT2A	1.24e-04	40	146	4	CID000002758
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HG-U133A	SQLE RAB11FIP1 ACSL3 LPIN1 H1-0 AFF1 PALLD	1.49e-04	177	146	7	1951_UP
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	ANK3 MYCBP2 EXPH5 SQLE UBN1 UBTF KMT2A	1.60e-04	179	146	7	4585_DN
Drug	Trichostatin A, Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	LIMA1 MTSS1 RAB11FIP1 ACSL3 LPIN1 H1-0 PADI2	1.60e-04	179	146	7	1112_UP
Drug	noralfentanil	CYP3A7 CYP3A4 CYP3A5	1.64e-04	17	146	3	CID000162172
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A	LIMA1 MTSS1 RAB11FIP1 ARMCX2 H1-0 CACNA1G PADI2	1.71e-04	181	146	7	6276_UP
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; PC3; HT_HG-U133A	UBR2 ARHGAP32 EXPH5 ZNF318 MCM10 KIF14 AFF1	1.71e-04	181	146	7	1791_DN
Drug	Hydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; HL60; HG-U133A	SQLE RAB11FIP1 ACSL3 LPIN1 PGRMC2 MACF1 ANKRD12	1.89e-04	184	146	7	1772_DN
Drug	Corticosterone [50-22-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A	LIMA1 PPFIBP2 SQLE POM121L2 ZNF318 LPIN1 H1-0	1.89e-04	184	146	7	3244_UP
Drug	scriptaid; Up 200; 10uM; PC3; HT_HG-U133A	SQLE RAB11FIP1 DMXL1 ACSL3 LPIN1 ANKRD12 PALLD	1.89e-04	184	146	7	6919_UP
Drug	aflatoxin	CYP3A7 CYP3A4 CYP3A5	1.96e-04	18	146	3	CID000014421
Drug	Azamulinum	CYP3A7 CYP3A4 CYP3A5	1.96e-04	18	146	3	CID003086060
Drug	Fenthion	CYP3A7 CYP3A4 CYP3A5	1.96e-04	18	146	3	ctd:D005284
Drug	Y 290	BCR KMT2A AFF1	1.96e-04	18	146	3	CID000114729
Drug	AC1L1SX8	CYP3A7 CYP3A4 CYP3A5	1.96e-04	18	146	3	CID000060278
Drug	trichostatin A; Up 200; 0.1uM; MCF7; HG-U133A	LIMA1 ARMCX2 NKIRAS2 DMXL1 PGRMC2 H1-0 AFF1	2.02e-04	186	146	7	332_UP
Drug	Hycanthone [3105-97-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A	ARHGAP32 ANK3 EXPH5 ITGB4 UBTF KIF14 ANKRD12	2.16e-04	188	146	7	5691_DN
Drug	AH23848 hemicalcium salt hydrate; Up 200; 1uM; PC3; HT_HG-U133A	GGA2 CYP3A4 EMSY DENND4C B9D1 PCNX1 FOXG1	2.16e-04	188	146	7	6885_UP
Drug	Monobenzone [103-16-2]; Down 200; 20uM; MCF7; HT_HG-U133A	MAP9 GGA2 EXPH5 SQLE H1-0 KIF14 ANKRD12	2.23e-04	189	146	7	5312_DN
Drug	rabeprazole	CYP3A7 CYP3A4 CYP3A5	2.32e-04	19	146	3	CID000005029
Drug	Alexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; PC3; HT_HG-U133A	TBC1D9B GGA2 MTSS1 ZNF318 ITGB2 EMSY CDC40	2.38e-04	191	146	7	7397_DN
Drug	azacyclonol	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000015722
Drug	hydroxytrimipramine	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000160610
Drug	dithianon	CYP3A4 ATP2C1	2.43e-04	4	146	2	CID000018771
Drug	potassium ferricyanide	CYP3A4 GUCY1A1	2.43e-04	4	146	2	ctd:C028033
Drug	N-octylimidazole	CYP3A5 MTSS1	2.43e-04	4	146	2	CID000161351
Drug	territrem B	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000114734
Drug	B253	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000021540
Drug	5-methoxyflavone	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000094525
Drug	Ro 23-7637	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000129491
Drug	N-ethyl-3-toluamide	CYP3A4 CYP3A5	2.43e-04	4	146	2	ctd:C454678
Drug	CQA 206-291	CYP3A4 CYP3A5	2.43e-04	4	146	2	CID000146782
Drug	eucalyptol	CYP3A4 CYP3A5	2.43e-04	4	146	2	ctd:C010087
Drug	0175029-0000 [211245-78-2]; Up 200; 1uM; PC3; HT_HG-U133A	GGA2 LARP6 ATP2C1 HEATR6 GTF3C2 CDC40 MAP3K9	2.46e-04	192	146	7	7392_UP
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	TBC1D9B ANK2 KIF1A EXPH5 EMSY TBC1D22A PADI2	2.46e-04	192	146	7	2699_DN
Drug	PNU-0230031 [267429-39-0]; Down 200; 10uM; PC3; HT_HG-U133A	GGA2 ARMCX2 LPIN1 H1-0 PAK2 KIF14 PCNX1	2.46e-04	192	146	7	4288_DN
Drug	1-alpha-25-dihydroxycholecalciferol	CYP3A7 CYP3A4 CYP3A5 SQLE MTSS1 DENND4C ACSL3 LRIG3 ATP2C1 SEMA6D NAV3 SNX9 WDSUB1 PADI2 PALLD MYBL2	2.48e-04	909	146	16	CID000002524
Drug	0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A	GGA2 CYP3A4 CYP3A5 MTSS1 DIDO1 GTF3C2 MAP3K9	2.54e-04	193	146	7	4289_UP
Drug	Isoetharine mesylate salt [7279-75-6]; Down 200; 12uM; HL60; HT_HG-U133A	MYBBP1A IMPDH1 ANK3 KIF1A SPAG8 ITGB4 B9D1	2.62e-04	194	146	7	2711_DN
Drug	Moricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; HL60; HT_HG-U133A	POM121L2 BCR ITGB4 HEATR6 TTC23 UBTF PCNX1	2.62e-04	194	146	7	2959_UP
Drug	Procainamide hydrochloride [614-39-1]; Down 200; 14.8uM; PC3; HT_HG-U133A	ARHGAP32 TBC1D9B GGA2 ZNF318 ITGB4 B9D1 PCNX1	2.62e-04	194	146	7	4602_DN
Drug	Vidarabine [5536-17-4]; Down 200; 15uM; PC3; HT_HG-U133A	MAP9 TBC1D9B GGA2 NKIRAS2 UBTF H1-0 MED12	2.70e-04	195	146	7	5850_DN
Drug	Azlocillin sodium salt [37091-65-9]; Down 200; 8.2uM; HL60; HT_HG-U133A	TBC1D9B IMPDH1 CYP3A4 EXPH5 PPFIBP2 ITGB4 AFF1	2.70e-04	195	146	7	2727_DN
Drug	Flufenamic acid [530-78-9]; Down 200; 14.2uM; HL60; HG-U133A	GGA2 DMXL1 UBTF PGRMC2 MACF1 PCNX1 ANKRD12	2.70e-04	195	146	7	1420_DN
Drug	CID5475388	CYP3A7 CYP3A4 CYP3A5	2.72e-04	20	146	3	CID005475388
Drug	fentichlor	CYP3A7 CYP3A4 CYP3A5 FOXG1	2.75e-04	49	146	4	CID000007329
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; HL60; HT_HG-U133A	ARHGAP32 GGA2 LPIN1 TBC1D22A UBTF MACF1 PCNX1	2.79e-04	196	146	7	2511_DN
Drug	1,1-dimethylbiguanide hydrochloride; Down 200; 10uM; MCF7; HG-U133A	GGA2 MYCBP2 ACTL6A NKIRAS2 LPIN1 ATP2C1 PGRMC2	2.79e-04	196	146	7	2_DN
Drug	Todralazine hydrochloride [3778-76-5]; Down 200; 14.8uM; HL60; HT_HG-U133A	MYBBP1A DIDO1 RAB11FIP1 CDC40 UBTF XAF1 MED12	2.79e-04	196	146	7	1841_DN
Drug	Cefixime [79350-37-1]; Up 200; 8.8uM; PC3; HT_HG-U133A	CYP3A7 GGA2 CYSLTR1 SPAG8 SEMA6D PCNX1 FOXG1	2.79e-04	196	146	7	4567_UP
Drug	Pentetic acid [67-43-6]; Up 200; 10.2uM; PC3; HT_HG-U133A	GGA2 CYP3A5 LPIN1 SYCP2 MAP3K9 PCNX1 XAF1	2.79e-04	196	146	7	4669_UP
Drug	Etomidate [33125-97-2]; Up 200; 16.4uM; HL60; HT_HG-U133A	CYP3A5 BCR SYCP2 SEMA6D UBTF PADI2 PALLD	2.79e-04	196	146	7	2958_UP
Drug	Vinpocetine [42971-09-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A	GGA2 KIF1A MTSS1 ZNF318 TTC23 TBC1D22A FOXG1	2.87e-04	197	146	7	7213_DN
Drug	DO 897/99; Down 200; 8.2uM; MCF7; HT_HG-U133A	LIMA1 TBC1D9B NACA DIDO1 EMSY DMXL1 PADI2	2.87e-04	197	146	7	7462_DN
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Up 200; 9uM; PC3; HT_HG-U133A	GGA2 KIF1A CYP3A5 ZNF318 PCNX1 XAF1 PADI2	2.87e-04	197	146	7	4668_UP
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Up 200; 9.6uM; PC3; HT_HG-U133A	CYP3A7 KIF1A CYP3A5 CYSLTR1 ARMCX2 KCNB1 PCNX1	2.87e-04	197	146	7	5765_UP
Drug	Pivampicillin [33817-20-8]; Up 200; 8.6uM; HL60; HT_HG-U133A	KIF1A POM121L2 SPAG8 TTC23 TBC1D22A B9D1 PADI2	2.87e-04	197	146	7	2945_UP
Disease	tacrolimus measurement	CYP3A7 CYP3A4 CYP3A5	4.54e-07	4	144	3	EFO_0008458
Disease	metabolonic lactone sulfate measurement	CYP3A7 CYP3A4 CYP3A5	1.04e-04	19	144	3	EFO_0800659
Disease	Meckel syndrome (is_implicated_in)	B9D1 KIF14	1.41e-04	4	144	2	DOID:0050778 (is_implicated_in)
Disease	Epidermolysis Bullosa	EXPH5 ITGB4	1.41e-04	4	144	2	C0014527
Disease	estrone conjugate measurement	CYP3A7 CYP3A4	1.41e-04	4	144	2	EFO_0007971
Disease	Precursor B-cell lymphoblastic leukemia	BCR KMT2A AFF1	1.42e-04	21	144	3	C1292769
Disease	tauro-beta-muricholate measurement	CYP3A7 CYP3A4	2.34e-04	5	144	2	EFO_0800213
Disease	glyco-beta-muricholate measurement	CYP3A7 CYP3A4	2.34e-04	5	144	2	EFO_0800569
Disease	Epidermolysis Bullosa Simplex	EXPH5 ITGB4	2.34e-04	5	144	2	C0079298
Disease	blood nickel measurement	MUC16 ITGB2 SPATS2L XAF1 USH2A	3.14e-04	120	144	5	EFO_0007583
Disease	dehydroisoandrosterone sulfate DHEA-S measurement	CYP3A7 CYP3A4	3.50e-04	6	144	2	EFO_0021119
Disease	androstenediol (3beta,17beta) monosulfate (1) measurement	CYP3A7 CYP3A4	3.50e-04	6	144	2	EFO_0800294
Disease	congenital heart disease (implicated_via_orthology)	USP17L21 USP17L12 USP42 KMT2A	3.68e-04	69	144	4	DOID:1682 (implicated_via_orthology)
Disease	pentachlorophenol measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022071
Disease	parathion measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022070
Disease	potassium chromate measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022072
Disease	mercuric chloride measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022068
Disease	heptachlor epoxide measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022067
Disease	methoxychlor measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022069
Disease	4,6-dinitro-o-cresol measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022053
Disease	2,4,5-trichlorophenol measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022052
Disease	azinphos methyl measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022055
Disease	aldrin measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022054
Disease	dicofol measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022060
Disease	disulfoton measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022062
Disease	dieldrin measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022061
Disease	endrin measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022064
Disease	endosulfan measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022063
Disease	heptachlor measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022066
Disease	ethion measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022065
Disease	chlorpyrifos measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022057
Disease	cadmium chloride measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022056
Disease	diazinon measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022059
Disease	dibutyl phthalate measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0022058
Disease	environmental exposure measurement	MUC16 SPATS2L XAF1 USH2A	4.56e-04	73	144	4	EFO_0008360
Disease	DDT metabolite measurement	MUC16 SPATS2L XAF1 USH2A	4.80e-04	74	144	4	EFO_0007886
Disease	X-24574 measurement	CYP3A7 CYP3A4	4.89e-04	7	144	2	EFO_0800897
Disease	testosterone measurement	CYP3A7 LIMA1 SPEM3 ANK2 ANK3 CYP3A4 USP43 ZNF318 SEMA6D GTF3C2 CEP112 AFF1 MACF1 USH2A MED12 WDR72	5.12e-04	1275	144	16	EFO_0004908
Disease	pneumococcal meningitis	MRO TBC1D22A	6.50e-04	8	144	2	EFO_1001114
Disease	xerostomia	EGFLAM WDR72	6.50e-04	8	144	2	EFO_0009869
Disease	Burkitt Lymphoma	BCR KMT2A AFF1	7.22e-04	36	144	3	C0006413
Disease	Developmental delay (disorder)	ACTL6A PNPT1 UBTF	7.83e-04	37	144	3	C0424605
Disease	influenza A severity measurement	ZFYVE28 GUCY1A1	8.33e-04	9	144	2	EFO_0007743
Disease	underweight body mass index status	ANK2 NRXN3	8.33e-04	9	144	2	EFO_0005936
Disease	androstenediol (3beta,17beta) disulfate (1) measurement	CYP3A7 CYP3A4	8.33e-04	9	144	2	EFO_0800278
Disease	4-androsten-3alpha,17alpha-diol monosulfate (3) measurement	CYP3A7 CYP3A4	1.04e-03	10	144	2	EFO_0022090
Disease	5alpha-androstan-3beta,17alpha-diol disulfate measurement	CYP3A7 CYP3A4	1.04e-03	10	144	2	EFO_0800289
Disease	cortical thickness	COL12A1 MYCBP2 NCKAP5 ZNF318 UBN1 MRO TBC1D22A CEP112 UBTF NAV3 B9D1 KMT2A AFF1 MACF1	1.13e-03	1113	144	14	EFO_0004840
Disease	Neurodevelopmental Disorders	ANK2 SETBP1 KMT2A FOXG1	1.13e-03	93	144	4	C1535926
Disease	DNA repair protein RAD51 homolog 4 measurement	CYP3A7 CYP3A4	1.26e-03	11	144	2	EFO_0801531
Disease	androstenediol (3beta,17beta) monosulfate (2) measurement	CYP3A7 CYP3A4	1.26e-03	11	144	2	EFO_0800295
Disease	primary ovarian insufficiency (implicated_via_orthology)	USP17L21 USP17L12 USP42	1.48e-03	46	144	3	DOID:5426 (implicated_via_orthology)
Disease	5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement	CYP3A7 CYP3A4	1.51e-03	12	144	2	EFO_0800291
Disease	acute myeloid leukemia (implicated_via_orthology)	KMT2A MYBL2	1.51e-03	12	144	2	DOID:9119 (implicated_via_orthology)
Disease	blood cobalt measurement	MUC16 SPATS2L XAF1 USH2A	1.54e-03	101	144	4	EFO_0007577
Disease	diastolic blood pressure, systolic blood pressure	ANK2 ANK3 CNTROB LYRM2 LRIG3 PNPT1 KCNB1 SETBP1 AFF1 MAP4K2	1.72e-03	670	144	10	EFO_0006335, EFO_0006336
Disease	middle temporal gyrus volume measurement, Alzheimer's disease biomarker measurement	MYCBP2 CNKSR2	1.78e-03	13	144	2	EFO_0006514, EFO_0010316
Disease	androstenediol (3alpha, 17alpha) monosulfate (3) measurement	CYP3A7 CYP3A4	1.78e-03	13	144	2	EFO_0800293
Disease	5alpha-pregnan-3beta,20beta-diol monosulfate (1) measurement	CYP3A7 CYP3A4	1.78e-03	13	144	2	EFO_0800284
Disease	X-21470 measurement	CYP3A7 CYP3A4	2.07e-03	14	144	2	EFO_0800817
Disease	5alpha-androstan-3alpha,17alpha-diol monosulfate measurement	CYP3A7 CYP3A4	2.07e-03	14	144	2	EFO_0800283
Disease	16a-hydroxy DHEA 3-sulfate measurement	CYP3A7 CYP3A4	2.38e-03	15	144	2	EFO_0800301
Disease	X-21410 measurement	CYP3A7 CYP3A4	2.71e-03	16	144	2	EFO_0800813
Disease	andro steroid monosulfate C19H28O6S (1) measurement	CYP3A7 CYP3A4	2.71e-03	16	144	2	EFO_0800305
Disease	PR interval	MYCBP2 USP28 NCKAP5 UBXN11 CEP95 AFF1 MACF1 CACNA1G	3.06e-03	495	144	8	EFO_0004462
Disease	Meckel syndrome type 1	B9D1 KIF14	3.44e-03	18	144	2	C3714506
Disease	Myeloid Leukemia	SETBP1 KMT2A	3.44e-03	18	144	2	C0023470
Disease	Leukemia, Monocytic, Chronic	SETBP1 KMT2A	3.44e-03	18	144	2	C0023466
Disease	5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement	CYP3A7 CYP3A4	3.44e-03	18	144	2	EFO_0800288
Disease	etiocholanolone glucuronide measurement	CYP3A7 CYP3A4	3.83e-03	19	144	2	EFO_0800362
Disease	Global developmental delay	ACTL6A PNPT1 UBTF ACTL6B	4.17e-03	133	144	4	C0557874
Disease	androsterone glucuronide measurement	CYP3A7 CYP3A4	4.24e-03	20	144	2	EFO_0800317
Disease	chronic myeloid leukemia (is_implicated_in)	CYP3A5 BCR	4.67e-03	21	144	2	DOID:8552 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
KMSISNPKTISRLIP	EGFLAM	296	Q63HQ2
LTTLLLKTIPMSTKP	ADGRG4	756	Q8IZF6
LLPMKPLKAAATTSQ	BCR	521	P11274
SLLSPTFTSGKLKEM	CYP3A5	131	P20815
SQKTPPSMRLKLIAS	ACTL6B	366	O94805
MTENSTSAPAAKPKR	H1-0	1	P07305
KTPPSMRLKLIANNT	ACTL6A	371	O96019
SPVGLSTMAKQSLRK	ACTL9	311	Q8TC94
IPVSLMTPKFSLRKS	CEP112	226	Q8N8E3
PIPSEAKMRLKATLT	ATF7	251	P17544
SSMKRKLPFTISPSR	ANKRD12	56	Q6UB98
LQSNTKKMPSLPSLQ	CCDC87	556	Q9NVE4
ASSSQRKRMSPKPEL	CETN2	11	P41208
HPPKKTLTRSMTSLA	DMXL1	1276	Q9Y485
MLKKLLSTQVPASFS	ARMCX2	541	Q7L311
TMIPVLTSKKASELP	ATP2C1	16	P98194
LDKLPMASTITKIPS	IQCG	106	Q9H095
IPLKPTVKMLERSSS	PZP	1396	P20742
PASKFSLQKTLSMPS	RIC1	1026	Q4ADV7
FLSLSSETKPKLMTP	EDC4	581	Q6P2E9
MKLSATVIFNPKSPT	ZFYVE28	511	Q9HCC9
MSKSSFQPPKLRDKT	MAP4K2	226	Q12851
KSKIPVRTMPTSTPA	ANK2	3301	Q01484
KAATSPKATMSPRHL	MISP	456	Q8IVT2
SPSTIKLTMASVVKP	MUC16	1261	Q8WXI7
LKSPAPSILKNRMSN	KIF14	296	Q15058
MKPKPRILSIKSTSS	MAP9	146	Q49MG5
RASSLSESSPPKAMK	LIMA1	366	Q9UHB6
MLKALPLKSSLTPSS	RPS6KC1	466	Q96S38
KLTVNMLPSFTKTPM	LRIG3	596	Q6UXM1
KKGTIPSLSIFTLMI	DDX58	356	O95786
SLLSPTFTSGKLKEM	CYP3A4	131	P08684
RLKVSMAFTPSALPI	ITGAE	681	P38570
KMIPKSSFSINSLVP	FOXG1	11	P55316
RLMAPESIKPLTTSK	PCNX1	706	Q96RV3
SIPPSKKEILRQMSS	PDC	41	P20941
LKSLTMDPHKLPSSS	MTSS1	226	O43312
LTMKPSSSLPTILRT	MUC3A	2891	Q02505
PATSLPRMKKRDFSL	PGRMC2	91	O15173
PSQSLSKPITMEKAS	NAV3	561	Q8IVL0
PKSYSSSLMDQIPIK	INTS2	676	Q9H0H0
TKLKSPLITSPMFRN	NRXN3	1526	Q9Y4C0
LMTLTLKDPSPKTRA	HEATR6	461	Q6AI08
SKMTQPQSKSAFPLS	NKIRAS2	166	Q9NYR9
SPKKTIFLLTNPMKL	LRRC74A	401	Q0VAA2
SPHKMKESSPLSSRK	LPIN1	286	Q14693
LPPSMTILKLSQNKF	LRRK2	1171	Q5S007
VTNQKKPTPFSSRMS	EXPH5	106	Q8NEV8
KSPGTSPLLSRKMQT	LARP6	446	Q9BRS8
NMPSSSKTKPVLSSL	MED12	1406	Q93074
SMRVKLQPASSSKLP	GGA2	541	Q9UJY4
PTSQPKQKRTSMISF	MRO	16	Q9BYG7
ASSKPVMGLKSPRLV	FAM83A	291	Q86UY5
MGSPKPAIKSISASA	MCM10	546	Q7L590
IPGTKKFLLLMASTS	PADI2	481	Q9Y2J8
GRKLSKSPSMSISEP	ARHGAP32	896	A7KAX9
TVLMAPRSAKPALLK	ITGB4	886	P16144
KMASPAYTPLTTTAK	PPFIBP2	796	Q8ND30
PSKIPTMSKKTTTAS	MACF1	7366	Q9UPN3
LTKRNSPLTVPMFLS	MYBBP1A	986	Q9BQG0
TRKITLKTPLISSPM	IMPDH1	56	P20839
KSISSPVSKRKPAMS	PALLD	111	Q8WX93
TKAPKAMTPSRIADS	NCOA4	471	Q13772
PSIIMSSQKALVSGK	NDUFA7	66	O95182
NPLFKSATTTVMNPK	ITGB2	751	P05107
KLAKPLSSLTPLIMA	PAK2	501	Q13177
PRTSKGKPLAMVSAA	IGSF10	261	Q6WRI0
SLQKSTAVMLPKTSP	IGSF10	1226	Q6WRI0
PMLPSIISKDSSTKS	IGSF10	1296	Q6WRI0
SILKMYGSPLKTPSV	HEATR5A	651	Q86XA9
SPKSSMKTNNPLKLR	KCNB1	656	Q14721
FGLLPLSMTSTRKAK	COG1	911	Q8WTW3
SMAASPSPKKDVLSL	CACNA1G	2351	O43497
RFKSPRNLKTSDPTM	COL12A1	1086	Q99715
RVTTKKAPSPSQLSM	COL20A1	641	Q9P218
PKPSFQSSAKMTKTS	GAS2L3	511	Q86XJ1
LPLEQSKSFMTTKPA	CMYA5	1861	Q8N3K9
RSMPASFLPPSSVKK	SQLE	386	Q14534
VMVPKSILAKPSSSP	DIDO1	1006	Q9BTC0
NSITKSPPLMAKRTK	DENND4C	736	Q5VZ89
LMTLKKTFVLAPSSV	ANKH	391	Q9HCJ1
PKLRTPIKMGISAST	ANK3	3716	Q12955
PNEMLSKKALASPSS	CEP95	201	Q96GE4
DPKKLNHTPVSTMSS	ATF7IP	981	Q6VMQ6
MAASRLPPATLTLKQ	LYRM2	1	Q9NU23
VKMSRKPRASSPLSN	CSAG2	66	Q9Y5P2
FLPASTAPMQGKRKS	KMT2A	596	Q03164
IKMASTRLPSPKSLV	EMSY	376	Q7Z589
MPALSTPKTTRNLKQ	CCDC168	1681	Q8NDH2
SLLSPTFTSGKLKEM	CYP3A7	131	P24462
KRTIPMFVPESTSKL	B9D1	116	Q9UPM9
ILMSGKKTFSLSPTV	S1PR3	96	Q99500
MDKRKSLINSRSSPP	MAP3K9	536	P80192
PVHKTKVPLAMASSL	CNTROB	756	Q8N137
VMPLSKPVPATKLST	KIF1A	1106	Q12756
SPSASTPMINKTGFK	LRRC8D	246	Q7L1W4
SLSTPLKLIGVTKMN	FAM167A	191	Q96KS9
QMPTAKPLETKSFTP	TAF3	256	Q5VWG9
LSPPKMQKISSTELH	USH2A	1246	O75445
STSTSLPRGILKMKN	UTP18	226	Q9Y5J1
MQAFLKGTSISTKPP	RFC4	1	P35249
LSQSMSVLPTSKPEK	RAB11FIP1	231	Q6WKZ4
TKDSLKSMTLPSYRP	RAB11FIP1	386	Q6WKZ4
ASSSSMKIPLNKFPG	SNX9	196	Q9Y5X1
LLTMQLKSPMPSSTT	SPAG8	316	Q99932
FKAPGASKSSLLPRM	SPATA31C2	826	B4DYI2
KAANPKMVSSLPSTA	SPATS2L	401	Q9NUQ6
SPALAPGKLSRFMKT	NCKAP5	836	O14513
MRRSLSSSKPHLKPA	NCKAP5	1251	O14513
TTSMTSVPKPLKFLR	PSMD2	86	Q13200
KLMMSTLPKSLSLPT	MYBL2	596	P10244
KLKSPLITSPMFRNV	NRXN3	521	Q9HDB5
SLMHLTKSPSSKPSL	CDC40	36	O60508
KTKSSMLPPKQALAS	FAM120AOS	171	Q5T036
KMTITLKRELPSSSP	PIWIL4	186	Q7Z3Z4
MHNTMKSKSPLPLTL	MYCBP2	3146	O75592
SKTKPSPSQFMPLVV	PNPT1	86	Q8TCS8
TRPSAFKPLMKNGTL	POM121L2	191	Q96KW2
PLKTTPMIAPFSSKQ	POM121L2	586	Q96KW2
LPSPLSISTKSKMTF	TBC1D9B	361	Q66K14
KLVSTMKASGTLPSQ	EIF4ENIF1	486	Q9NRA8
MKASGTLPSQPKVSR	EIF4ENIF1	491	Q9NRA8
KPSRPSSQSSKKEML	AFF1	851	P51825
SSKPSTMKLKHTINP	ACSL3	6	O95573
VILTSSPFLMAKPQK	CYSLTR1	151	Q9Y271
LTLKKRPQSMLTSAP	CNKSR2	291	Q8WXI2
MSPSAKKRPKNSRVS	TP53TG5	1	Q9Y2B4
MKDSKSLSLPILRPA	PLEKHG5	161	O94827
TMSVSSKVTKPIPRS	USP42	571	Q9H9J4
TTSRAKQGPFKTMPL	USP43	801	Q70EL4
PSFRLTPIDSKKMRN	TMPRSS11F	166	Q6ZWK6
TPSHSKLTPKLETMT	ZBP1	386	Q9H171
SLLQTPKSTLSLMKS	SPEM3	1036	A0A1B0GUW6
MSSPKRSSKPSMSLA	SRRM5	1	B3KS81
RSSLEKGQPSSKMTP	SYCP2	981	Q9BX26
APRSKNKTLDPLLMS	XAF1	231	Q6GPH4
PVTSLLMSPEKFKLR	WDR72	511	Q3MJ13
APASKMLTLLTSAKV	USP17L21	261	D6R901
KSKPLTSSRSSMEMP	USP28	511	Q96RU2
SMKSSSENTLPLKGP	ZNF518A	1036	Q6AHZ1
LLRSTAKMPTTPVKA	TBC1D22A	41	Q8WUA7
APASKMLTLLTSAKV	USP17L12	261	C9JPN9
MAIRKKSTKSPPVLS	TRAM1	1	Q15629
SLMASPYKSSSPKLS	UBN1	1021	Q9NPG3
QPDLSSEMSKVSKPR	GTF3C2	81	Q8WUA4
MLSTAPKVASKPRQA	TTC23	406	Q5W5X9
KKRTSPMTNLVLPSA	WDSUB1	441	Q8N9V3
NTLKPFSRVLTPKEM	TMIGD3	246	P0DMS9
SEMRAPPAATNSSKK	UBTF	546	P17480
TLSSAKPFMSLVKSL	TEX2	181	Q8IWB9
GMVLKVLAKTSPFSL	SEMA6D	446	Q8NFY4
FNAVKKMRESSPTSP	UBR2	996	Q8IWV8
RPAKTNDTMTKVPFL	SETBP1	1021	Q9Y6X0
TMSKPAPLNTFLSIK	ZNF318	1366	Q5VUA4
MAVPSSRILQLSKPK	THEG	261	Q9P2T0
MSSPLASLSKTRKVP	UBXN11	1	Q5T124
RKMSSVSLLFKRTPP	WDR64	956	B1ANS9
SVHMKSTKPSLSPSK	GUCY1A1	256	Q02108
KQAPALSMTSSSPKK	NACA	906	E9PAV3
LSMTSSSPKKARATP	NACA	911	E9PAV3